Abbott Laboratories
ABT
$133.58
-$0.36-0.27%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.33B | 9.23B | 1.65B | 1.30B | 1.23B |
| Total Depreciation and Amortization | 756.00M | 807.00M | 801.00M | 805.00M | 805.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 289.00M | 593.00M | 117.00M | 141.00M | 304.00M |
| Change in Net Operating Assets | -953.00M | -7.76B | 141.00M | -288.00M | -1.31B |
| Cash from Operations | 1.42B | 2.87B | 2.71B | 1.96B | 1.03B |
| Capital Expenditure | -484.00M | -720.00M | -556.00M | -533.00M | -398.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | 0.00 | 1.00M | -- |
| Other Investing Activities | 14.00M | -146.00M | -38.00M | 79.00M | -27.00M |
| Cash from Investing | -470.00M | -866.00M | -594.00M | -453.00M | -425.00M |
| Total Debt Issued | 1.00M | 1.00M | 1.00M | 221.00M | -- |
| Total Debt Repaid | -1.04B | -614.00M | 42.00M | -61.00M | -127.00M |
| Issuance of Common Stock | 287.00M | 25.00M | 92.00M | 13.00M | 134.00M |
| Repurchase of Common Stock | -280.00M | -315.00M | -751.00M | -3.00M | -226.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.03B | -958.00M | -960.00M | -961.00M | -957.00M |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.06B | -1.86B | -1.58B | -791.00M | -1.18B |
| Foreign Exchange rate Adjustments | 24.00M | -83.00M | 36.00M | -13.00M | -36.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.08B | 58.00M | 571.00M | 703.00M | -612.00M |